Literature DB >> 3098412

Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin.

K E Wallner, G C Li.   

Abstract

The effects of drug exposure duration and of heat and drug sequencing on hyperthermic potentiation of mitomycin-C (MMC) and cisplatin (DDP) were studied. Heating for 1 h at 42 degrees C was combined with drug exposure times of 1, 2, 4, or 8 h. For both DDP and MMC, hyperthermic potentiation was greatest when heating was done during drug exposure. Dose enhancement ratios for both drugs at 1% survival were highest with the shortest drug exposure times and decreased as the drug exposure time increased from 1 to 8 h. For DDP, the dose enhancement ratio decreased from 1.9 with a 1-h drug exposure to 1.2 with an 8-h drug exposure. For MMC, the dose enhancement ratio decreased from 1.8 to 1.5 as the drug exposure duration was increased from 1 to 8 h. Our results suggest that thermochemotherapy in vivo is likely to be most effective with rapid infusions of DDP or MMC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3098412

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Hyperthermia in cancer therapy.

Authors:  J Otte
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

Review 2.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

3.  Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells.

Authors:  S Ohno; Z H Siddik; Y Kido; L A Zwelling; J M Bull
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination.

Authors:  Y Yonemura; T Fujimura; S Fushida; S Takegawa; T Kamata; K Katayama; T Kosaka; A Yamaguchi; K Miwa; I Miyazaki
Journal:  World J Surg       Date:  1991 Jul-Aug       Impact factor: 3.352

5.  Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia.

Authors:  Y Kido; H Kuwano; Y Maehara; M Mori; H Matsuoka; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.

Authors:  I Takahashi; Y Maehara; H Kusumoto; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line.

Authors:  E Kimura; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8.

Authors:  Haitao Qiu; Xiaokang Shen; Bing Chen; Tianming Chen; Guodong Feng; Shilin Chen; Dongjie Feng; Qiaoshu Xu
Journal:  Apoptosis       Date:  2021-03-29       Impact factor: 4.677

9.  Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer.

Authors:  A Marinelli; F R Dijkstra; J H van Dierendonck; P J Kuppen; C J Cornelisse; C J van de Velde
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

10.  Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells.

Authors:  T Kusumoto; Y Maehara; H Baba; I Takahashi; H Kusumoto; S Ohno; K Sugimachi
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.